glp-1 injections atlanta Medical Weight Loss with in Atlanta, GA Top-Rated Weight Loss Program In
Description
But again, kudos to my team
He said those drugs have high sales amounts per prescription, but emphasized that the increased volume of GLP-1s has a "minimal impact" on Rite Aid's gross profit
Type 2 diabetes (34.80%) and weight loss (14.71%) emerged as the most predominant indications, while others accounted for 3.92%, and unknown or missing constituted 46.57% (Table 1)
In 2025, 49% of large employers covered GLP-1 medications, up from 44% in 2024 and 41% in 2023.
Recent Developments In February 2026 , Pfizer announced positive Phase 2b trial results for its ultra-long-acting injectable GLP-1 (PF-08653944), demonstrating significant weight loss with monthly dosing
About 35.4% of Black residents and 34.3% of Hispanic residents in the state live with obesity
